Open an account

Vanda Pharmaceuticals

VNDA · NASDAQ

$4.17+$0.08 (+1.96%)TodayMarket closed ·
Prev close $4.09

About VNDA

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 533 full-time employees. The company went IPO on 2006-04-12. The firm's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Employees
533
Headquarters
WASHINGTON, Washington Dc
Listed
Apr 12, 2006
Sector
Health Care
Industry
Biotechnology
Website
vandapharma.com

VNDA key statistics

Market cap
243.66M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.09M
Volume
857.21K
Open price
$4.11
High today
$4.32
Low today
$4.10
52 Week high
$9.94
52 Week low
$4.00

Vanda Pharmaceuticals (VNDA) at a glance

Vanda Pharmaceuticals (VNDA) last traded at $4.17, with a market cap of 243.66M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.10 and $4.32. The current price is 1.7% above the day's low and 3.4% below its high.

Volume so far is 857.21K shares, below the average of 1.09M shares a day.

Over the past year Vanda Pharmaceuticals has ranged from $4.00 to $9.94, and now sits 3% of the way up that range.

Vanda Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$1.04 per share against an estimate of -$0.5993.

The average analyst price target is $11.98, 187.4% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 5 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 7 analystsAvg $11.98
Low
$5.81
Now
$4.17
High
$21.00

VNDA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 34.8% on average.

  1. Q3 FY24: reported -$0.09 per share against an estimate of -$0.1666
  2. Q4 FY24: reported -$0.08 per share against an estimate of -$0.1088
  3. Q1 FY25: reported -$0.50 per share against an estimate of -$0.6086
  4. Q2 FY25: reported -$0.46 per share against an estimate of -$0.3638
  5. Q3 FY25: reported -$0.38 per share against an estimate of -$0.4624
  6. Q4 FY25: reported -$0.46 per share against an estimate of -$1.35
  7. Q1 FY26: reported -$0.82 per share against an estimate of -$0.7018
  8. Q2 FY26: reported -$1.04 per share against an estimate of -$0.5993

VNDA news

  • Vandana Singh

    Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint

  • Press releasePRNewswire

    Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

  • Press releasePRNewswire

    Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

  • Vandana Singh

    Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug

  • Press releasePRNewswire

    Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

  • Press releasePRNewswire

    Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

  • Press releasePRNewswire

    Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

  • Press releasePRNewswire

    NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

Similar companies

Companies in the same industry as Vanda Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.